Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: monoclonal antibody therapeutics - Integral molecular

Next Previous
Search
Drug Profile

Research programme: monoclonal antibody therapeutics - Integral molecular

Latest Information Update: 12 Oct 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Integral Molecular
  • Class Analgesics; Antihyperglycaemics; Antivirals; Hepatoprotectants; Monoclonal antibodies
  • Mechanism of Action Cannabinoid receptor CB1 antagonists; GLUT4 stimulants; Immunomodulators; Membrane protein modulators; Purinergic P2X3 receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Metabolic disorders; Pain

Highest Development Phases

  • Research Chikungunya virus infections; Dengue; Ebola virus infections; Hepatitis C; Zika virus infection
  • No development reported Metabolic disorders; Neuropathic pain; Non-alcoholic steatohepatitis; Type 2 diabetes mellitus

Most Recent Events

  • 12 Oct 2023 Research programme: monoclonal antibody therapeutics - Integral molecular is available for licensing as of 10 Oct 2023. https://www.integralmolecular.com/partnering/
  • 05 Oct 2023 Early research development in Ebola-virus-infections, Chikungunya-virus-infections and Zika-virus-infection is still ongoing in USA (Parenteral) (Integral Molecular pipeline, October 2023)
  • 28 Jan 2023 No recent reports of development identified for research development in Metabolic-disorders in USA

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top